Immunology & Autoimmune
Part of Biotech - Drug Development
 JNJ | Johnson & Johnson | $0.6t | $253.31 | +1.1% | 7.5M |
 ABBV | ABBVIE INC. | $444.6b | $254.38 | +0.0% | 5.2M |
 AMGN | Amgen Inc | $195.4b | $364.85 | -1.5% | 2.1M |
 BMY | Bristol-Myers Squibb Co. | $117.7b | $60.89 | +0.5% | 9.8M |
 REGN | Regeneron Pharmaceuticals Inc | $65.4b | $676.50 | -0.3% | 479.2K |
 ROIV | Roivant Sciences Ltd. Common Shares | $25.5b | $34.52 | +1.7% | 2.5M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $10.0b | $133.78 | -0.1% | 1.7M |
 IBRX | ImmunityBio, Inc. Common Stock | $9.2b | $7.69 | +2.8% | 8.3M |
 TGTX | TG Therapeutics, Inc. | $8.4b | $55.43 | -0.1% | 1.3M |
 IMVT | Immunovant, Inc. Common Stock | $7.9b | $40.07 | +3.3% | 741.7K |
 PTGX | Protagonist Therapeutics, Inc | $7.9b | $140.96 | +6.5% | 402.9K |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $7.7b | $100.27 | +6.4% | 937.8K |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $5.7b | $92.00 | +11.8% | 2.4M |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $5.3b | $105.00 | +10.5% | 916.5K |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 RCUS | Arcus Biosciences, Inc. | $3.9b | $27.36 | +2.7% | 610.0K |
 ALMS | Alumis Inc. Common Stock | $3.6b | $28.68 | +5.5% | 867.0K |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $3.3b | $28.15 | +2.6% | 1.0M |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $3.1b | $38.17 | -1.7% | 1.2M |
 CLDX | Celldex Therapeutics, Inc | $2.9b | $35.56 | -0.2% | 933.8K |
 NKTR | Nektar Therapeutics | $2.4b | $68.23 | +1.7% | 450.0K |
 BHVN | Biohaven Ltd. | $2.2b | $15.39 | +9.0% | 3.2M |
 AUPH | Aurinia Pharmaceuticals Inc | $2.2b | $16.07 | +0.1% | 621.8K |
 ADMA | ADMA Biologics, Inc. | $1.9b | $8.73 | -1.0% | 2.3M |
 ANAB | AnaptysBio, Inc. Common Stock | $1.7b | $58.38 | +7.1% | 669.2K |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.6b | $19.68 | +3.6% | 642.3K |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $1.6b | $30.00 | +4.4% | 648.6K |
 SEPN | Septerna, Inc. Common Stock | $1.5b | $33.41 | +5.9% | 266.1K |
 JBIO | Jade Biosciences, Inc. Common Stock | $1.4b | $20.56 | +1.9% | 565.3K |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.3b | $14.89 | +4.3% | 684.2K |
 XNCR | Xencor, Inc. | $1.2b | $17.93 | +16.8% | 1.3M |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.1b | $17.58 | +7.7% | 516.8K |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $1.0b | $18.39 | +8.4% | 1.1M |
 DBVT | DBV Technologies S.A. | $1.0b | $14.76 | -0.7% | 502.2K |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $5.94 | -1.9% | 3.0M |
 CLYM | Climb Bio, Inc. Common Stock | $0.7b | $12.69 | +0.8% | 1.3M |
 ACRS | Aclaris Therapeutics, Inc. | $0.7b | $5.67 | +6.0% | 1.1M |
 IMMX | Immix Biopharma, Inc. Common Stock | $0.7b | $10.25 | +1.9% | 946.3K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.7b | $40.53 | -2.5% | 153.7K |
 STTK | Shattuck Labs, Inc. Common Stock | $0.7b | $7.17 | +6.5% | 2.8M |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $0.5b | $7.50 | 0.0% | 783.1K |
 CABA | Cabaletta Bio, Inc. Common Stock | $0.5b | $2.83 | +6.9% | 3.1M |
 EVMN | Evommune, Inc. | $478.7m | $12.13 | +3.7% | 639.7K |
 IPSC | Century Therapeutics, Inc. Common Stock | $441.9m | $2.26 | -0.2% | 979.4K |
 FBRX | Forte Biosciences, Inc. Common Stock | $435.2m | $48.78 | +8.7% | 562.6K |
 ENTA | Enanta Pharmaceuticals, Inc | $424.0m | $13.74 | +4.2% | 152.3K |
 UPB | Upstream Bio, Inc. Common Stock | $376.6m | $7.01 | -3.3% | 299.5K |
 PALI | Palisade Bio, Inc. Common Stock | $363.2m | $1.97 | +3.7% | 2.0M |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $355.8m | $5.45 | +3.8% | 686.9K |
 IFRX | InflaRx N.V. Common Stock | $329.9m | $1.88 | -2.9% | 735.2K |